Determination of protein expression changes due to treatment with chromatin remodeling inhibitor FHD-286 in patient-derived mutant NPM1 and FLT-ITD-expressing AML cells
Ontology highlight
ABSTRACT: We treated patient-derived mutant NPM1-and FLT3-ITD expressing AML cells with a chromatin remodeling inhibitor, FHD-286, at a dose of 100 nM, for 48 hours to determine FHD-286-mediated changes to the AML proteome.
INSTRUMENT(S):
ORGANISM(S): Homo Sapiens (human)
DISEASE(S): Acute Leukemia
SUBMITTER:
Antrix Jain
LAB HEAD: Warren Fiskus
PROVIDER: PXD047967 | Pride | 2025-05-06
REPOSITORIES: Pride
ACCESS DATA